Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Lloyd's of London hails 'outstanding' year despite profits hit

(Sharecast News) - Lloyd's of London reported a slide in profits on Thursday, following a raft of catastrophes in the US. The centuries-old insurance and reinsurance market said underwriting profits fell 10% in 2024 to £5.3bn, with pre-tax profits also 10% lower, at $9.6n.

Lloyd's said the major claims ratio rose to 7.8% due to "significant" catastrophe events during the year, including hurricanes Milton and Helen and the Baltimore Bridge collision.

However, the underlying combined ratio - a key measure of underwriting profitability, excluding major claims - was 79.1%, an improvement on 2023's 80.5%. Lloyd's said the ratio reflected the market's "ongoing focus on consistent profitability".

Gross written premiums also improved, rising to £55.5bn from 2023's £52.1bn.

Outgoing chief executive John Neal said the market had delivered "another year of outstanding financial performance, with a superb combined ratio, underlying combined ratio and attritional loss ratio supporting a capital position claims reserve strength that is as strong as it has ever been".

Neal, who took up the role in 2018, announced he was quitting one of the City's biggest jobs in January. His leaving to become chief executive of insurer Aon.

Former Treasury secretary Charles Roxburgh, who takes over as chair in May, will lead the search for his successor.

Lloyd's is made up for around 50 insurance companies and more than 380 registered brokers.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.